• Humacyte posted a net loss of USD 17.62 million, swinging from net income of USD 39.14 million a year earlier, while operating loss widened to USD 28.94 million.
• Revenue edged down to USD 495,000 from USD 517,000, as product revenue rose to USD 493,000 from USD 147,000 while contract revenue fell to USD 2,000 from USD 370,000.
• Cost of goods sold climbed to USD 2.04 million from USD 147,000, while R&D expense increased to USD 19.46 million from USD 15.42 million on USD 4.3 million in higher material costs tied to non-commercial manufacturing runs and process improvement.
• Cash, cash equivalents and restricted cash totaled USD 48.9 million, with net cash used of USD 2 million; commercial Symvess sales reached USD 500,000 on 29 units versus USD 100,000 on five units.
• Restructuring cut headcount about 25% and reduced expected spending by USD 14.3 million for the rest of 2026; top-line interim Phase 3 hemodialysis results are slated for June 11, 2026, alongside a USD 1.48 million minimum Symvess purchase commitment for a Saudi Arabia clinical evaluation program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130700PRIMZONEFULLFEED9719024) on May 13, 2026, and is solely responsible for the information contained therein.